Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07213466CT.gov Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder | — | Recruiting | — | — | — |
NCT01866098CT.gov Naltrexone for Antipsychotic-Induced Weight Gain | — | Completed | — | — | — |
NCT00793780CT.gov Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia | — | Completed | — | — | — |
NCT00453609CT.gov Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI) | — | Completed | — | — | — |
NCT00453804CT.gov Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Schizoaffective Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Naltrexone (this asset) | Mayo Clinic | Approved | BB · 69 |
| Paliperidone | Luye Pharma Group Ltd. | P4 | BBB |
| Risperidone | Lyndra Inc. | P4 | BBB |
| Lurasidone | University of Texas Southwestern Medical Center | P4 | BBB |
| Dexmedetomidine | BioXcel Therapeutics Inc | P4 | BBB |
| Raloxifene | Iris Sommer | P4 | BBB |
| Olanzapine | The Royal Ottawa Mental Health Centre | P4 | BBB |
| Quetiapine | Otsuka Pharmaceutical Development & Commercialization, Inc. | P4 | BBB |
| Ziprasidone | Centre for Addiction and Mental Health | P4 | BBB |
+42 more in the Schizoaffective Disorder cohort
Other indications for Naltrexone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Alcohol Dependence | — | P4 | BBB · 79 |
| Osteoarthritis | — | P4 | BBB · 75 |
| Rheumatoid Arthritis | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Naltrexone in Schizoaffective Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/naltrexone-schizoaffective-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →